Complement and its receptors: New insights into human disease

Annual Review of Immunology

Volumn 32, Issue , 2014, Pages 433-459

  Holers, V Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Anaphylatoxins; Complement activation pathways; Complement regulatory proteins; Disease models; Inflammation; Therapeutics; Thrombotic microangiopathies

Indexed keywords

ARGININE CARBOXYPEPTIDASE; CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR H; COMPLEMENT RECEPTOR; DECAY ACCELERATING FACTOR; ECULIZUMAB; FIBRINOGEN; ISONIAZID; PETROLEUM; TOLL LIKE RECEPTOR; VITRONECTIN;

ADAPTIVE IMMUNITY; ANGIONEUROTIC EDEMA; AUTOIMMUNE DISEASE; CELL REGENERATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MYELOOPTIC NEUROPATHY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RARE DISEASE; REGULATORY MECHANISM; REVIEW; SEPSIS; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROTEIN BINDING; RECEPTORS, COMPLEMENT; SIGNAL TRANSDUCTION;

EID: 84896970663     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032713-120154     Document Type: Review

References (151)

1. Fearon DT, Locksley RM. 1996. The instructive role of innate immunity in the acquired immune response. Science 272: 50-54
2. Brown EJ. 1991. Complement receptors and phagocytosis. Curr. Opin. Immunol. 3:76-82
3. Carroll MC. 1998. The role of complement and complement receptors in the induction and regulation of immunity. Annu. Rev. Immunol. 16:545-68
4. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, et al. 2001. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2:739-45
5. Botto M, Walport MJ. 2002. C1q, autoimmunity and apoptosis. Immunobiology 205:395-406
6. Davies KA, Peters AM, Beynon HLC, Walport MJ. 1992. Immune complex processing in patients with systemic lupus erythematosus. J. Clin. Investig. 90:2075-83
7. Holers VM, Carroll MC. 2005. Innate autoimmunity. Adv. Immunol. 86:137-57
8. Markiewski MM, Lambris JD. 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30:286-92
9. Holers VM. 2005. Complement receptors and the shaping of the natural antibody repertoire. Springer Sem. Immunopathol. 26:405-23
10. Strey CW, Markiewski M, Matellos D, Tudoran R, Spruce LA, et al. 2003. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198:913-23
11. Yanai R, Thanos A, Connor KM. 2012. Complement involvement in neovascular ocular diseases. Adv. Exp. Med. Biol. 946:161-83
12. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11:785-97
13. NorisM, Remuzzi G. 2008. Translationalmini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin. Exp. Immunol. 151:199-209
14. PickeringMC, Cook HT. 2008. Translationalmini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin. Exp. Immunol. 151:210-30
15. Rosse WF,Nishimura J. 2003. Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems. Int. J. Hematol. 77:113-20
16. Papadopoulos MC, Verkman AS. 2012. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 11:535-44
17. Holers VM. 2003. The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 107:140-51
18. Ricklin D, Lambris JD. 2013. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 735:1-22
19. Botto M, KirschfinkM,Macor P, PickeringMC, Wurzner R, Tedesco F. 2009. Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 46:2774-83
20. Zipfel PF, Hallstrom T, Riesbeck K. 2013. Human complement control and complement evasion by pathogenic microbes: tipping the balance. Mol. Immunol. 56:152-60
21. Lachmann PJ, Hughes-Jones NC. 1984. Initiation of complement activation. Springer Semin. Immunopathol. 7:143-62
22. Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A. 2012. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 217:1122-28
23. Muller-Eberhard HJ. 1988. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57:321-47
24. Nilsson B, Ekdahl KN. 2012. The tick-over theory revisited: Is C3 a contact-Activated protein? Immunobiology 217:1106-10
25. Lachmann PJ. 2009. The amplification loop of the complement pathways. Adv. Immunol. 104:115-49
26. Ricklin D. 2012. Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 217:1057-66
27. Holers VM, Thurman JM. 2004. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol. Immunol. 41:147-52
28. Runza VL, SchwaebleW,MannelDN. 2008. Ficolins: novel pattern recognitionmolecules of the innate immune response. Immunobiology 213:297-306
29. Gadjeva M, Takahashi K, Thiel S. 2004. Mannan-binding lectin: a soluble pattern recognitionmolecule. Mol. Immunol. 41:113-21
30. Reid KBM, Turner MW. 1994. Mammalian lectins in activation and clearance mechanisms involving the complement system. Springer Semin. Immunopathol. 15:307-25
31. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. 2001. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am. J. Pathol. 159:1045-54
32. Jordan JE, Montalto MC, Stahl GL. 2001. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104:1413-18
33. Sahu A, Lambris JD. 2001. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180:35-48
34. Lea SM, Johnson S. 2012. Putting the structure into complement. Immunobiology 217:1117-21
35. Gros P, Milder FJ, Janssen BJ. 2008. Complement driven by conformational changes. Nat. Rev. Immunol. 8:48-58
36. Wetsel RA. 1995. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7:48-53
37. Morgan BP, Gasque P. 1997. Extrahepatic complement biosynthesis: where, when and why? Clin. Exp. Immunol. 107:1-7
38. Gadjeva M, Verschoor A, Brockman MA, Jezak H, Shen LM, et al. 2002. Macrophage-derived complement component C4 can restore humoral immunity in C4-deficient mice. J. Immunol. 169:5489-95
39. Li K, Sacks SH, Zhou W. 2007. The relative importance of local and systemic complement production in ischaemia, transplanation and other pathologies. Mol. Immunol. 44:3866-74
40. Laufer J, Katz Y, Passwell JH. 2001. Extrahepatic synthesis of complement proteins in inflammation. Mol. Immunol. 38:221-29
41. Holers VM. 1989. Complement receptors. Year Immunol. 4:231-40
42. Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. 1991. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 173:1083-89
43. Jozsi M, Prechl J, Bajtay Z, Erdei A. 2001. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J. Immunol. 168:2782-88
44. Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, et al. 2013. Human complement receptor type 1/CD35 is an Epstein-Barr virus receptor. Cell Rep. 3:371-85
45. Carroll MC. 2000. The role of complement in B cell activation and tolerance. Adv. Immunol. 74:61-88
46. Helmy KY, Katschke KJ, Gorgani NN, Klvajin NM, Elliott JM, et al. 2006. CRIg: a macrophage complement receptor required for phagocytosis and circulating pathogens. Cell 124:915-27
47. Karsten CM, Kohl J. 2012. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217:1067-79
48. Ward PA. 2009. Functions of C5a receptors. J. Mol. Med. 87:378
49. Sacks SH. 2010. Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur. J. Immunol. 40:668-70
50. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, et al. 2000. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406:998-1001
51. Thurman JM, Lenderink AM, Royer PA, Coleman KE, Zhou J, et al. 2007. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J. Immunol. 178:1819-28
52. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. 1996. Control of the complement system. Adv. Immunol. 61:201-83
53. Davis AE. 1988. C1 inhibitor and hereditary angioedema. Annu. Rev. Immunol. 6:595-628
54. Hourcade D, Holers VM, Atkinson JP. 1989. The regulators of complement activation (RCA) gene cluster. Adv. Immunol. 45:381-416
55. PangburnMK. 2002. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J. Immunol. 169:4702-6
56. Perkins SJ, Nan R, Li K, Khan S, Miller M. 2012. Complement Factor H-ligand interactions: selfassociation, multivalency and dissociation constants. Immunobiology 217:281-97
57. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, et al. 2011. Structural basis for engagement by complement factor H of C3b on a self-surface. Nat. Struct. Mol. Biol. 18:463-70
58. Pangburn MK, Rawal N, Cortes C, Alam MN, Ferreira VP, Atkinson MAL. 2009. Polyanion-induced self-Association of complement factor H: possible mechanism of host protection from an innate immune system. J. Immunol. 182:1061-68
59. Kemper C, Hourcade DE. 2008. Properdin: New roles in pattern recognition and target clearance. Mol. Immunol. 45:4048-56
60. Blom AM. 2004. Complement inhibitorC4b-binding protein-friend or foe in the innate immune system? Mol. Immunol. 40:1333-46
61. Morgan BP, Berg CW, Harris CL. 2005. "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 12:258-65
62. Inal JM, Hui KM, Miot S, Lange S, Ramirez MI, et al. 2005. Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. J. Immunol. 174:356-66
63. Holmquist E, Okroj M, Nodin B, Jirstrom K, Blom AM. 2013. Sushi domain-containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase. FASEB J. 27(6):2355-66
64. Matthews KW, Mueller-Ortiz SL, Wetsel RA. 2004. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol. Immunol. 40:785-93
65. Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, et al. 2011. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J. Clin. Investig. 121:3517-27
66. de Cordoba SR, Tortajada A, Harris CL, Morgan BP. 2012. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 217:1034-46
67. Jozsi M, Zipfel PF. 2008. Factor H family proteins and human diseases. Trends Immunol. 29:380-87
68. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. 2006. A common CFHhaplotype,with deletion ofCFHR1and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 38:1173-77
69. Skerka C, Zipfel PF. 2008. Complement factor H related proteins in immune diseases. Vaccine 26 (Suppl. 8):I9-14
70. Goicoechea de Jorge E, Caesar JJE, Malik TH, Paten M, Colledge M, et al. 2013. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc. Natl. Acad. Sci. USA 110:4685-90
71. Tortajada A, Yebenes H, Abarrategui-Garrido C, Anter J, Garcia-Fernandez JM, et al. 2013. C3 glomerulopathy-Associated CFHR1 mutation alters FHR oligomerization and complement regulation. J. Clin. Investig. 123:2434-46
72. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. 2007. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28:184-92
73. Schulz C, Engelmann B, Massberg S. 2013. Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. J. Thromb. Haemost. 11(Suppl. 1):233-41
74. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12:682-87
75. Takahashi K, Chang W-C, Takahashi M, Pavlov V, Ishida Y, et al. 2011. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 216:96-102
76. Shahl AL, Sartz L, Karpman D. 2011. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503-13
77. Amaru U, Flierl MA, Rittirsch D, Klos A, Chen H, et al. 2010. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185:5628-36
78. Barratt-Due A, Pischke SE, Brekke O-L, Thorgersen EB, Nielsen EW, et al. 2012. Bride and groom in systemic inflammation:The bells ring for complement and Toll in cooperation. Immunobiology 217:1047-56
79. Zhang X, Kimura Y, Fang C, Zhou L, Sfyroera G, et al. 2007. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110:228-36
80. Wang M, Krauss JL, Domon H, Hosur KB, Liang S, et al. 2010. Microbial hijacking of complement- Toll-like receptor crosstalk. Sci. Signal. 3(109):ra11
81. Song WC. 2012. Crosstalk between complement and Toll-like receptors. Tox. Path. 40:174-82
82. Fang C, Zhang X, Miwa T, SongWC. 2009. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and IL-6 production. Blood 114:1005-15
83. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J. 2005. C5a negatively regulates Toll-like receptor 4-induced immune responses. Immunity 22:415-26
84. Waggoner SN,CruiseMW, KasselR,Hahn YS. 2005. gC1q receptor ligation selectively down-regulates human IL-12 production through activation of the phosphoinositide 3-kinase pathway. J. Immunol. 175:4706-14
85. Dempsey P, Allison M, Akkaraju S, Goodnow C, Fearon D. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348-50
86. Phan TG, Grigorova I, Okada T, Cyster JG. 2007. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 8:992-1000
87. BaelderR, Fuchs B, BautschW,Zwirner J, Kohl J, et al. 2005. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J. Immunol. 174:783-89
88. Strainic MG, Shevach EM, An F, Lin F, Medof ME. 2013. Absence of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3+ regulatory T cells. Nat. Immunol. 14:162-71
89. Cardone J, Le Friec G, Kemper C. 2011. CD36 in innate and adaptive immunity: an update. Clin. Exp. Immunol. 164:301-11
90. Le Friec G, Sheppard D, Whiteman P, Karsten CM, Shamoun SA, et al. 2012. The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat. Immunol. 13:1213-21
91. Perkins SJ, Goodship THJ. 2002. Molecular modeling of mutations in the C-terminal domains of factor H of human complement: a new insight into hemolytic uremic syndrome. J. Mol. Biol. 316:217-24
92. PickeringMC, Goicoechea de Jorge E, Martinez-Barricarte R, Recalde S, Garcia-Layana A, et al. 2007. Spontaneous hemolytic uremic syndrome triggered by complement factorHlacking surface recognition domains. J. Exp. Med. 204:1249-56
93. Rose KL, Paixao-Cavalcante D, Fish J, Manderson AP, Malik TH, et al. 2008. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J. Clin. Investig. 118:608-18
94. Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, PickeringMC. 2010. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 6:494-99
95. Gale DP, Goicoechea de Jorge E, Cook HT, Martinez-Barricarte R, Hadjisavvas A, et al. 2010. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376:794-801
96. Malik TH, Lavin PJ, Goicoechea de Jorge E, Vernon KA, Rose KL, et al. 2012. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J. Am. Soc. Nephrol. 23:1155-60
97. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, NorisM, et al. 2008. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 111:624-32
98. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, et al. 2013 Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 8 3 e1001013
99. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. 2006. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp.Med. 203:2165-75
100. Qing X, Redecha PB, Burmeister MA, Tomlinson S, D'Agati VD, et al. 2011. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 79:331-39
101. Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, et al. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc. Natl. Acad. Sci. USA 108:8761-66
102. Risitano AM. 2012. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217:1080-87
103. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. 2007. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotech. 25:1256-64
104. Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, et al. 2009. Complement fraction 3 binding on erythrocytes as an additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113:4094-100
105. Zipfel PF, Skerka C, Hellwage J, Jokiranta ST, Meri S, et al. 2002. Factor H family proteins: on complement, microbes and human diseases. Biochem. Soc. Trans. 30:971-78
106. Nester CM, Brophy PD. 2012. Eculizumab in the treatment of aytpical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr. Opin. Pediatr. 25:225-31
107. Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. 2013. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am. J. Kidney Dis. 61:289-99
108. Pittock SJ, Lennon VA, McKeon A, Mandrekar J,Weinshenker BG, et al. 2013. Eculizumab in AQP4- IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 12:554-62
109. Christiansen SC, Zuraw BL. 2009. Update on therapeutic developments for hereditary angioedema. Allergy Asthma Proc. 30:500-5
110. Gehrs KM, Anderson DH, Johnson LV,Hageman GS. 2006. Age-related macular degeneration: emerging pathogenetic and therapeutic concepts. Ann. Med. 38:450-71
111. Khandhadia S, Lotery A. 2010. Oxidation and age-related macular degeneration: insights frommolecular biology. Expert Rev. Mol. Med. 12:e34
112. Jha P, Bora PS, Bora NS. 2007. The role of the complement system in ocular diseases including uveitis and macular degeneration. Mol. Immunol. 44:3901-8
113. Rohrer B, Coughlin B, Kunchithapautham K, LongQ,Tomlinson S, et al. 2011. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol. Immunol. 48:e1-e8
114. Bora NS, Kaliappan S, Jha P, Xu Q, Sohn JH, et al. 2006. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J. Immunol. 177:1872-78
115. Nozaki M, Raisler BJ, Sakuria E, Sarma JV, Barnum SR, et al. 2006. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA 103:2328-33
116. Cashman SM, Ramo K, Kumar-Singh R. 2011. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age-related macular degeneration. PLoS ONE 6:e19078
117. Joseph K, Kulik L, Couglin B, Coughlin B, Kunchithapautham K, et al. 2013. Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J. Biol. Chem. 288:12753-65
118. Bao L,Haas M, Kraus DM, Hack BK, Rakstang JK, et al. 2003. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J. Am. Soc. Nephrol. 14:670-79
119. Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. 2004. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 65:129-38
120. Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, et al. 2011. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 63:1076-85
121. Sekine H, Ruiz P, Gilkeson GS, Tomlinson S. 2011. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol. Immunol. 49:317-23
122. Calero I, Sanz I. 2010. Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov. Med. 10:416-24
123. Liu Z, Davidson A. 2011. BAFF and selection of autoreactive B cells. Trends Immunol. 32:388-94
124. Cohen-Solal J, Diamond B. 2011. Lessons from an anti-DNA autoantibody. Mol. Immunol. 48:1328-31
125. Carroll MC. 2004. A protective role for innate immunity in systemic lupus erythematosus. Nat. Rev. Immunol. 4:825-31
126. Prodeus A, Goerg S, Shen L-M, Pozdnyakova OO, Chu L, et al. 1998. A critical role for complement in maintenance of self-tolerance. Immunity 9:721-31
127. Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, et al. 2004. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity 37:111-23
128. Silman AJ. 1994. Epidemiology of rheumatoid arthritis. APMIS 102:721-28
129. Silman AJ, Hochberg MC. 1993. Rheumatoid arthritis. In Epidemiology of the Rheumatic Diseases, ed. AJ Silman, MC Hochberg, pp. 7-68. New York: Oxford Univ. Press
130. Arend WP. 2001. The innate immune system in rheumatoid arthritis. Arthritis Rheum. 44:2224-34
131. Firestein GS. 2003. Evolving concepts of rheumatoid arthritis. Nature 423:356-61
132. Cooke TD, Hurd ER, Jasin HE, Bienenstock H, Ziff M. 1975. Identification of immunoglobulins and complement in rheumatoid articular collagenous tissues. Arthritis Rheum. 18:541-51
133. Linton SM,Morgan BP. 1999. Complement activation and inhibition in experimental models of arthritis. Mol. Immunol. 36:905-14
134. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, et al. 2002. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 46:934-45
135. Banda NK, Thurman JM, Kraus D,Wood A, Carroll MC, et al. 2006. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collageninduced arthritis. J. Immunol. 177:1904-12
136. BandaNK, TakahashiK,Wood AK,HolersVM, Arend WP. 2007. Pathogenic complement activation in collagen antibody-induced arthritis inmice requires amplification by the alternative pathway. J. Immunol. 179:4101-9
137. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, et al. 2012. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J. Immunol. 188:1469-78
138. Happonen KE, Heinegard D, Saxne T, Blom AM. 2012. Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseases. Immunobiology 217:1088-96
139. Kuhn KA, Cozine CL, Tomooka B, Robinson WH,Holers VM. 2008. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. Mol. Immunol. 45:2808-19
140. Stevens B, AllenNJ, Vazquez LE, Howell GR,ChristophersonKS, et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131:1164-78
141. FonsecaMI, Ager RR, Chu SH, Yazan O, Sanderson SD, et al. 2009. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 183:1375-83
142. Fu W, Wojtkiewicz G, Weissleder R, Benoist C,MathisD. 2012. Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat. Immunol. 13:361-68
143. Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, et al. 2010. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116:1002-10
144. Taylor RP, Lindorfer MA. 2014. The role of complement in mAb-based therapies of cancer. Methods. 65:18-27
145. Elvington M, Huang Y, Morgan BP, Qiao F, van Rooijen N, et al. 2012. A targeted complementdependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 119:6043-51
146. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, et al. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9:1225-35
147. He S, Atkinson C, Qiao F, Cianflone K, Chen C, Tomlinson S. 2009. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J. Clin. Investig. 119:2304-16
148. Nilsson B, Ekdahl KN. 2012. Complement diagnostics: concepts, indications, and practical guidelines. Clin. Dev. Immunol. 2012:962702. doi: 10.1155/2012/962702
149. Parkes M, Cortes A, van Heel DA, Brown MA. 2013. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14:661-73
150. Thurman JM, Kulik L, Orth H, Wong M, Renner B, et al. 2103. Detection of complement activation using monoclonal antibodies against C3d. J. Clin. Investig. 123:2218-30
151. HolersVM,Rohrer B,Tomlinson S. 2103. CR2-mediated targeting of complement inhibitors: bench-tobedside using a novel strategy for site-specific complement modulation. Adv. Exp.Med. Biol. 735:137-54